Introduction
Since the introduction of melphalan in the 1960s, the management of myeloma patients has remained largely unchanged and has been based on the combination of melphalan and prednisone. Attempts were made to improve the outcome of myeloma patients with various chemotherapy combinations, but a meta-analysis showed that more complex combinations of chemotherapeutic agents at standard doses were not superior to melphalan and prednisone in terms of progression-free survival and overall survival (OS). 1 In the early 1990s, the introduction of high-dose melphalan with autologous stem cell transplantation improved the outcome of many myeloma patients who were eligible for this procedure and became a standard of care for younger patients. 2 Furthermore, the need for a simple and reproducible prognostication system for the risk stratification of myeloma patients, led to a collaborative project that resulted in the construction of the international staging system (ISS). 3 ISS is based on serum albumin and b2-microglobulin levels, is widely and readily available, and is applicable to both young and elderly patients treated either with conventional chemotherapy or with high-dose melphalan with autologous stem cell transplantation.
In 1999, thalidomide was introduced in the treatment of relapsed/refractory multiple myeloma 4 followed by two other novel drugs: bortezomib 5 and lenalidomide. 6 A recent update of the pivotal thalidomide trial showed that 10% of patients who were included in this study are still alive after almost a decade of follow-up. 7 The introduction of these drugs increased the treatment options for myeloma patients, initially for those who were relapsing or were refractory to primary therapy, and more recently for newly diagnosed patients. [8] [9] [10] [11] [12] [13] Although most studies that used novel agent-based regimens have shown an improvement in progression-free survival and some in OS, 10 until recently there was no clear evidence that the introduction of novel agents has indeed increased the OS of myeloma patients treated outside the context of clinical trials. Two recent reports indicated that there has been an improvement in the outcome of myeloma patients over the few last years, 14, 15 and a recent report from the Mayo Clinic indicated that the survival of patients with multiple myeloma treated at this major referral center has improved significantly over the last decade, and this improvement has been attributed to the introduction of novel agents. 16 However, patients treated in referral centers and those who are included in clinical trials often represent a selected patient population. Thus, there is a need to assess the impact of novel treatments in a population of unselected myeloma patients. Furthermore, the construction of ISS only included patients treated up to 2002 and only few patients could have received thalidomide. 3 Thus, ISS has not been validated as a prognostic tool in patients who have been treated upfront with novel agent-based therapies.
Therefore, we analyzed an unselected population of myeloma patients who were treated in several Greek hospitals to assess the effect of novel agents in the survival of a large unselected population of myeloma patients, and to validate the applicability of ISS in a cohort of myeloma patients who were treated with novel agent-based therapy.
Materials and methods
The analysis included 1376 patients with newly diagnosed symptomatic myeloma who have been entered prospectively in the database of the Greek myeloma study group, which is maintained at the Alexandra hospital, since January 1985. Patients were divided into two cohorts on the basis of whether they started treatment before or after the introduction of the first novel drug, thalidomide: 859 patients started treatment before 31 December 1999 (before the introduction of novel agents) and 517 patients after 1 January 2000 (after the introduction of novel agents), when thalidomide became available in Greece.
Response was defined as a X50% reduction in the serum monoclonal protein and X90% reduction in Bence Jones proteinuria. An approval was obtained from the Institutional Review Board/ Scientific Committee of Alexandra Hospital for the use of the medical records of patients.
Statistical analysis
Differences between the two groups were compared with the w 2 test for categorical variables using Fisher's exact test when appropriate. Continuous variables were compared between the groups with the use of Mann-Whitney test. Survival was calculated from the date of initiation of treatment until the date of death, by any cause, or until the date of last contact. Patients who were lost to follow-up were censored at the date of last contact. As death was because of myeloma or complications of treatment in 97% of patients, OS was used as an endpoint. Survival curves were plotted with the method of Kaplan and Meier and the log-rank test was used for comparisons among groups. Cox proportional hazards were used for the calculation of hazard ratios for each variable. A multivariate analysis was carried out by entering all variables that were associated with survival and were significant at 0.05 level into a Cox proportional hazard's model.
Results
Characteristics of the patients before and after novel agents are depicted in detail in Table 1 . Patients who started treatment before introduction of novel agents were younger (Po0.001), had hypercalcemia (P ¼ 0.039) and anemia (P ¼ 0.095) less often, lower levels of Bence Jones proteinuria (P ¼ 0.027) and less bone marrow plasma cell infiltration (P ¼ 0.030). One hundred and sixty seven patients (32%) who started treatment after the introduction of novel agents were treated upfront with novel drug-based regimens. The response to first-line treatment was significantly higher in the most recent patients (67 vs 56%, Po0.001) ( Table 1 ).
The median OS of patients who started treatment before novel agents was 36 months (95% CI 33-39) and of patients who started treatment after novel agents was 48 months (95% CI 32.5-64) (Po0.001) ( Figure 1 ). Other baseline factors that were associated with inferior survival in univariate analysis were age470 years (Po0.001), poor performance status (Po0.001), anemia (hemoglobin o10 g/100 ml, Po0.001), higher ISS stage (Po0.001), elevated creatinine (X2 mg/100 ml) (Po0.001), high lactate dehydrogenase (LDH) (X300 IU/l) (Po0.001), hypercalcemia (corrected serum Ca X11.5 mg/100 ml), light chain only myeloma (P ¼ 0.001), bone marrow plasma cells 440% (Po0.001) and Bence Jones proteinuria X2 g/day (Table 2) .
In multivariate analysis, which included all baseline factors that were significant in univariate analysis, factors independently associated with inferior outcome were age470 years (Po0.001), poor performance status (P ¼ 0.003), higher ISS stage (Po0.001), elevated creatinine (X2 mg/100 ml) (P ¼ 0.027), high LDH (X300 IU/l) (Po0.001), and whether patients started treatment before 31 December 1999 (when novel agents were introduced) (Po0.001). However, because of the significant proportion of patients with missing data for b2-microglobulin in the group of patients who started treatment before novel agents, we carried out a second analysis that did not include the ISS stage. Factors independently associated with inferior outcome included age470 years (Po0.001), poor performance status (Po0.003), anemia, elevated creatinine (X2 mg/100 ml) (P ¼ 0.027), high LDH (X300 IU/l) (Po0.001), bone marrow plasmacytosis (Po0.001) and again whether patients started treatment before novel agents (Po0.001) ( Table 3) . 
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To further examine the effect of novel agents across various risk groups, we analyzed for differences in survival in the groups before and after novel agents for known adverse factors. In patients p70 years of age, the median survival improved almost two-fold after novel agents (74 vs 39 months in group A, Po0.001). For patients p50 years of age, the median survival was 64.1 months for patients treated before the introduction of novel agents but it has not been reached for the more recent patients (P ¼ 0.037). However, for patients 470 years of age, the median survival for groups before and after novel agents was 26 and 33 months, respectively, but this did not reach statistical significance (P ¼ 0.27) ( Figure 2 ). We subsequently compared the outcome in the age group of patients o65 years, of 65-75 and of 475 years, for patients who were treated before and for those who were treated after the introduction of novel agents. For patients o65 years we found a significant improvement in the median survival for those who were treated after January 1st 2000 (median OS not reached, lower bound for 95% CI 480 months) compared with that of those who were treated before 31 December 1999 (median OS 42 months, Po0.001). For patients in the group of 65-75 years, patients who were treated after the introduction of novel agents had a trend for a better outcome (median OS of 38 vs 32 months for patients who started treatment before novel agents, P ¼ 0.086). However, for patients 475 years, there was no difference in the survival before (median OS of 24.5 months) or after the introduction of novel agents (median OS of 28 months, P ¼ 0.871).
To clarify whether an increase in early death rates of older patients treated after the introduction of novel agents may be responsible for this lack of significant benefit, we compared early death rates in older patients, defined as the percentage of patients who died within 2 months from the initiation of treatment: early death rate was 9% for both groups. On the basis of an analysis published earlier showing that a reduction in excess mortality was more pronounced among patients who survived the first year after diagnosis, 14 we carried out a landmark analysis that included patients who survived more than 12 months after treatment initiation; in patients o70 years, the median survival was 48 months before novel agents, whereas it has not been reached for patients treated after the introduction of novel agents (Po0.001). However, in patients older than 70 years, the median survival was 42 months for patients treated before novel agents and 38 months for patients treated after novel agents were introduced (P ¼ 0.442), for those who survived at least the first year after initiation of treatment for symptomatic multiple myeloma.
Improved survival in patients after the introduction of novel agents was more pronounced in female (P ¼ 0.001) than in male (P ¼ 0.062) patients (Table 4) . After the introduction of novel agents, significant survival improvement was observed in patients with adverse features, such as anemia, high LDH, extensive bone marrow plasmacytosis, renal impairment, those with IgA myeloma or those with light chain only myeloma. However, this improvement was more pronounced when these features were absent ( Abbreviations: ISS, international staging system; LDH, lactate dehydrogenase.
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The second objective of our analysis was to validate the applicability of ISS in patients who were treated after novel agents were introduced, which included patients who had the opportunity to receive novel drug-based regimens either upfront or at a later stage of their disease: 34.5% of patients were rated as ISS stage I, 22.2% as ISS stage II and 43.3% as ISS stage III. The 5-year survival rate was 66% for ISS stage I patients, 45% for ISS stage II patients and 18% for ISS stage III patients (Po0.001) (Figure 3 ). When ISS was applied only to those patients who were actually treated upfront with novel agent-based treatments, the 4-year survival rate was 85, 61 and 26% for ISS stage I, II and III patients, respectively, (P ¼ 0.001) (Figure 4 ).
Discussion
We found that during the last decade there was a significant improvement in the outcome of patients who were treated for symptomatic multiple myeloma, resulting in an overall increase of median survival by 1 year. This benefit was observed despite the presence of more unfavorable characteristics in patients who were treated after the introduction of novel agents. Survival improvement was more pronounced in younger patients, reaching an absolute increase of 35 months, and in female patients (from 36 to 59 months). These findings confirm the observations of Kumar et al. 16 Since novel agents were available after 1999, we can conclude that the reason for this significant survival benefit is mainly because of the addition of novel drugs, either at relapse or at upfront. The significant survival benefit of our younger patients likely reflects both the increased numbers of patients who underwent high-dose melphalan with autologous stem cell transplantation and those who were exposed to novel drugs. However, we observed an improvement in the survival that is significantly higher than what would have been expected by the effect of autologous stem cell transplantation alone, a survival benefit of 1-1.5 years has been found in some prospective transplant trials, 2,17 whereas our patients who werep70 years old had an absolute increase in their median survival by 35 months. This observation favors a higher effect of novel agents. We found a 7-month survival improvement in older patients, which was similar to that observed by Kumar et al. 16 In our series, this difference did not reach statistical significance, obviously because of the smaller number of patients. In two other studies that were based on analyses from Cancer Registries, 14, 15 a lack of survival benefit in older patients was found despite the significant improvement in younger patients. This difference among younger and older patients was not because of increased toxicity in our elderly patients; early death rates were similar in older patients before or after novel agents, whereas in a landmark analysis, a survival benefit could not be observed in older patients who survived for more than 12 months. Elderly patients are more likely to have co-morbid conditions that limit their treatment options and are more likely to have a poor performance status. 14 We also observed an improvement in the survival of patients with several adverse features, such as patients with renal impairment, extensive marrow infiltration, high LDH, anemia and poor performance status. However, this improvement was more pronounced in patients who did not present with these adverse features. Our data showed that patients with anemia, renal impairment, high LDH and high tumor load, who were treated during the last decade, had a median survival of o3 years indicating the need for further treatment innovations.
Our results confirm earlier reports showing an improvement in the outcome of myeloma patients over the last few years. [14] [15] [16] However, in our analysis we included only symptomatic, unselected patients from several hospitals, many of whom were treated outside clinical trials. One third of them had poor performance status and/or were older than 70 years. In referral centers and in clinical trials, fitter and younger patients may be over-represented. Furthermore, as we included only patients who had symptomatic disease and as we assessed survival from the date of first treatment and not the date of diagnosis, we excluded patients with asymptomatic myeloma who are usually followed without treatment for a median of 2-3 years before the development of symptomatic disease. Although our data provide further evidence of the significant effect of novel agents in the survival of patients with myeloma, other variables too may have contributed to the improved survival. Over the last decade, the supportive care of myeloma patients has improved with the widespread use of bisphosphonates, wider application of growth factors and more aggressive treatment of myelomarelated renal failure. 16 Our second objective was the validation of ISS in the era of novel agents. ISS is an established, reproducible and widely available risk stratification system; however, it was constructed from databases of patients treated up to 2002, when only a few Improved survival of myeloma patients after the introduction of novel drugs and the ISS E Kastritis et al patients could have been exposed to thalidomide and with almost 70% of patients being derived from clinical trial registries. 3 In our current analysis, we showed that ISS is applicable in patients who had access to novel agents during the course of their disease and we confirmed the Mayo Clinic data. 16 Furthermore, we found that ISS is valid in patients who were actually treated upfront with novel agent-based therapy. Thus, ISS remains a significant prognostication tool, although more sophisticated methods, such as karyotype and fluorescent in situ hybridization abnormalities or gene expression-profiling methods, may be more powerful. 18, 19 Despite the fact that new drugs have shown that they may be able to overcome, to some extent, negative prognostic factors, such as b2-microglobulin and chromosomal abnormalities, we found that novel agents could not fully overcome the negative prognostic effect of highrisk ISS. Although ISS stage III patients had a clear survival benefit after novel agents were introduced, further confirmation of this finding is needed. The applicability of ISS in the era of novel agents also permits for comparisons with older treatment approaches. We found that patients staged as ISS III, had an absolute increase in their median survival by 12 months, whereas in patients with ISS stage I or II, this benefit was significantly greater. Thus, even in the era of novel agents, ISS stage III patients have a poor outcome with a median survival of o3 years.
In conclusion, the introduction of novel agents has significantly increased the survival of myeloma patients, although this improvement is mainly evident in younger patients. In such patients, especially when adverse features are absent, myeloma is becoming a chronic disease. However, the outcome of older patients and of those with adverse features remain unsatisfactory. There is clearly a need for innovative clinical trials, which will be designed specifically for such patients. The widely available and reproducible ISS is applicable in patients treated with novel agent-based regimens and can be used for the staging of such patients.
